<DOC>
	<DOCNO>NCT02173028</DOCNO>
	<brief_summary>Patients treat accord clinical practice participate center international guideline treatment heart failure.The present analysis provide collection data change drug therapy `` Cardiac Resynchronization Therapy '' ( CRT ) procedure , sign symptom intolerance prescribe medication .</brief_summary>
	<brief_title>RESynchronizaTiOn theRapy bEta-blocker Titration</brief_title>
	<detailed_description>The treatment chronic heart failure currently base use ACE ( Angiotensin Converting Enzyme ) inhibitors beta-blockers . Although therapy universally accept 10-20 % patient may intolerant . Moreover , majority patient treat dos show effective control clinical trial . Although possible even low dos neurohumoral inhibitor still effective placebo , great benefit obtain maximum dos . Therefore , generally recommend agent use recommended dos find effective controlled study . There many reason lack prescription neurohumoral inhibitor use non-optimal dos . These include inadequate clinical management , low tolerance drug . As far beta-blockers , poor tolerability least two main cause : 1 ) effect relate heart failure ( eg , bradycardia , AtrioVentricular ( AV ) block , bronchial asthma ) , 2 ) acute negative inotropic effect , cause deterioration hemodynamic parameter . The primary objective analysis demonstrate cardiac resynchronization therapy ( CRT ) may allow titration beta-blockers ( carvedilol bisoprolol ) optimal dosage , least effective dose , patient heart failure treat maximal dos beta-blockers indication CRT accord current international guideline . The secondary objective evaluate effectiveness remote monitor telemedicine system facilitate automatic titration beta-blockers comparison standard approach , consist periodic outpatient visit . The strategy adopt depend availability remote monitor system standard clinical practice participate center . In addition , evaluate clinical response CRT , depend optimal sub-optimal dosage beta-blockers .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Patients optimal therapy heart failure ( diuretic , ACE inhibitors aldosterone antagonist ) , stable dose previous month ; Successfully implant CRTD accord current European Society Cardiology ( ESC ) guideline ; New York Heart Association ( NYHA ) functional class : II , III IV ; Left Ventricular Ejection Fraction ( LVEF ) ≤ 35 % ; Duration ventricular depolarization wave ( QRS ) ≥ 120ms ( NYHA III IV ) ≥ 150ms NYHA II ; Patients chronic atrial fibrillation eligible study undergo ablation ; 18 year Failure comply schedule followup ; Life expectancy le 12 month ; Pregnant woman ; Tricuspid valve mechanic ; Severe aortic stenosis valve disease ; Patients already receive CRT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Beta Blocker Intolerance ;</keyword>
	<keyword>Remote Patient Management system ;</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
</DOC>